News

Kainos Begins Phase 1 Trial of Therapy for Parkinson’s Disease

The first patient has been dosed in a two-part Phase 1 clinical trial evaluating KM-819, Kainos Medicine’s potential disease-modifying treatment for Parkinson’s disease (PD), the company announced in a press release. The dose-escalation clinical trial (NCT03022799) will evaluate the drug’s safety, tolerability, and biochemical properties following single…

More than 300 Genes Impact Toxicity of Protein Linked to Brain Function, Study Finds

Researchers have identified more than 300 genes that influence alpha-synuclein’s toxicity, and among them are many known to predispose individuals to Parkinson’s disease (PD), researchers said. The finding provides new insight into what mechanisms lead to the disease. The hallmark of Parkinson’s disease is the formation of alpha-synuclein protein aggregates, which…

EU Calls for Multinational Research Projects in Neurodegenerative Diseases

The European Union Joint Programme — Neurodegenerative Disease Research (JPND) has launched a call for proposals for “multinational research projects for pathway analysis across neurodegenerative diseases,” such as Parkinson’s disease (PD). Neurodegenerative diseases are a health, social, and economic problem in Europe and across the globe. With this in…